3630 results for «578»
3630 results
Adopting a step-by-step approach for successful redo TAVI
21 May 2026 – From EuroPCR 2026
This session outlines a systematic step-by-step approach for redo TAVI procedures, including detailed pre-procedural CT analysis. It addresses challenges associated with failing short and tall-frame valves, and discusses coronary protection and leaflet modification techniques critical for successful reinterventions.
Managing difficult TAVI scenarios
19 May 2026 – From EuroPCR 2026
Focused on complex TAVI cases, this session reviews guideline recommendations for TAVI in younger patients, strategies for managing concomitant coronary artery disease, and considerations for treating asymptomatic severe aortic stenosis. Real-world cases illustrate clinical decision-making and outcomes.
Interventional therapy for hypertension
19 May 2026 – From EuroPCR 2026
This session addresses interventional therapies for hypertension, emphasizing patient selection for renal denervation and integration of this technique within comprehensive hypertension management. It also reviews available renal denervation technologies, optimal procedural approaches, and considerations for interventional treatment of renal artery stenosis.
Insight from recent evidence in structural heart disease: indications for LAA closure (CHAMPION) and PCI in TAVI candidates (PRO-TAVI)
20 May 2026 – From EuroPCR 2026
This session reviews recent evidence impacting the management of structural heart disease, focusing on left atrial appendage (LAA) closure indications and PCI considerations in transcatheter aortic valve implantation (TAVI) candidates. It discusses optimal strategies for coronary artery disease in TAVI patients and evaluates findings from the...
Insight from recent evidence in coronary artery disease: value of DCB for de novo lesions (SELUTION) and imaging for left main PCI (OPTIMAL)
21 May 2026 – From EuroPCR 2026
This session reviews pivotal recent evidence impacting daily practice in coronary artery disease management. It discusses the role of drug-coated balloons (DCB) for de novo lesions as evaluated in the SELUTION trial and evaluates intracoronary imaging strategies for left main PCI as presented in the OPTIMAL...
Identifying and planning protected temporary mechanical circulatory support-based procedures in high-risk patients
21 May 2026 – From EuroPCR 2026
This session provides an in-depth update on protected temporary mechanical circulatory support-based procedures in high-risk cardiac patients. It covers patient identification criteria, device selection, and multidisciplinary planning to optimize outcomes in protected PCI, ventricular ablation, and surgical contexts.
Spotlight - TAVI durability: contemporary evidence and future directions
21 May 2026 – From EuroPCR 2026
Focusing on TAVI durability, this session reviews recent clinical evidence from randomized trials and large registries, examining procedural and device-related factors influencing long-term valve performance. It also discusses challenges in follow-up and implications for future trial designs and device monitoring.
Antithrombotic therapy after TAVI: optimal agents, regimens, and patient selection
20 May 2026 – From EuroPCR 2026
This session critically evaluates antithrombotic therapy following TAVI, addressing optimal agents and regimens tailored to patients with and without atrial fibrillation. It also reviews clinical presentations and management of valve thrombosis post-TAVI, using guideline-based approaches and real-world cases to individualize patient care.
DCB: what we know and what we do not know
22 May 2026 – From EuroPCR 2026
This session provides a detailed update on drug-coated balloons (DCB) in interventional cardiology, covering the latest clinical data and trials. It identifies scenarios where DCB use is most effective and offers guidance on optimizing procedural techniques to enhance clinical outcomes.
Asymptomatic high-risk patients: can CT coronary angiography improve our practice?
21 May 2026 – From EuroPCR 2026
This session examines the role of cardiac computed tomography (CT) coronary angiography in improving clinical practice for asymptomatic high-risk patients. It discusses detection of vulnerable plaque features, the importance of inflammation and physiology in risk assessment, and explores individualized treatment pathways including PCI, medical therapy, or...
Physiological vs. anatomical assessment of multivessel disease patients
21 May 2026 – From EuroPCR 2026
This session delves into the comparative benefits of physiological versus anatomical assessment in patients with multivessel coronary disease, focusing particularly on myocardial infarction cases. Attendees will explore how coronary physiology can guide complete revascularisation, the added value of physiological assessment beyond conventional angiography, and the selection...
Hybrid percutaneous revascularisation: combining DES and DCB for optimal results
21 May 2026 – From EuroPCR 2026
This session delves into hybrid percutaneous revascularisation techniques that combine drug-eluting stents (DES) and drug-coated balloons (DCB) to achieve optimal clinical results. It highlights the clinical and anatomical scenarios suited for hybrid PCI, provides a step-by-step procedural approach, and discusses the potential benefits of integrating these...
All you need to know of DAPT in ACS
21 May 2026 – From EuroPCR 2026
This session provides an in-depth review of dual antiplatelet therapy (DAPT) in acute coronary syndrome (ACS), focusing on strategies for safe de-escalation and P2Y12 inhibitor monotherapy to reduce bleeding risk without compromising ischemic protection. It also covers optimizing antithrombotic therapy in patients on oral anticoagulation and...
A critical appraisal of the recent evidence in the LAA closure field
20 May 2026 – From EuroPCR 2026
This session critically appraises recent evidence in the left atrial appendage (LAA) closure field, focusing on landmark trials such as CHAMPION-AF and CLOSURE AF. It discusses how these findings may influence patient selection and clinical practice, offering guidance on integrating new evidence into decision-making for stroke...
Ambiguous left main lesions: how to assess severity and make the right decision
21 May 2026 – From EuroPCR 2026
Addressing the complexities of ambiguous left main coronary lesions, this session elucidates the integration of physiology, intracoronary imaging, and CT scanning for comprehensive assessment. It highlights multimodality diagnostic strategies and decision-making frameworks to guide appropriate revascularization.
Imaging-guided strategy for understanding coronary calcification
21 May 2026 – From EuroPCR 2026
Focusing on coronary calcification, this session teaches the application of CT and intracoronary imaging to characterize calcium patterns, select appropriate modification tools, and assess procedural success. It emphasizes imaging-guided strategies to optimize treatment of calcified coronary lesions.
TAVI: LIVE Educational Case from Cleveland Clinic - London, UK
22 May 2026 – From EuroPCR 2026
This educational session from the Cleveland Clinic focuses on transcatheter aortic valve implantation (TAVI) in patients with significant landing zone calcification. It presents a detailed operator strategy and live case demonstrating the optimal use of a third generation intra-annular self-expanding valve, alongside approaches to coronary artery...
Challenges of multivessel disease in ACS
21 May 2026 – From EuroPCR 2026
Dedicated to the challenges of multivessel disease in acute coronary syndrome (ACS), this session explores strategies to identify culprit versus non-culprit lesions and plan multivessel revascularisation using physiology, intravascular imaging, and artificial intelligence. It further discusses the timing considerations for revascularisation, whether ad-hoc or staged, illustrated...
Routine primary PCI: what can go wrong?
21 May 2026 – From EuroPCR 2026
This session offers an in-depth examination of potential complications during routine primary PCI, focusing on prevention and management strategies. Key learning points include understanding no-reflow phenomena, managing STEMI in post-CABG patients, and handling thrombus burden effectively. Real-world cases illustrate decision-making processes and therapeutic approaches to optimize...
Spectrum of cardiogenic shock
21 May 2026 – From EuroPCR 2026
This session delves into the broad spectrum of cardiogenic shock phenotypes, emphasizing the importance of selecting appropriate left ventricular support tailored to specific clinical scenarios. It offers critical insights into the timing of mechanical circulatory support and revascularisation strategies to optimize patient outcomes.
